Navigation Links
Lotus Pharmaceuticals Preparing to Apply for National Exchange Listing
Date:10/22/2010

BEIJING, Oct. 22 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that the Company's Board of Directors has accepted the resignation of Dr. Ian Ashley from the Board.

Chairman and CEO Mr. Zhongyi Liu stated, "Dr. Ashley has served as a valued member of the Board for four years, and we sincerely appreciate his service. We are preparing to apply for a listing on a national securities exchange and are adding experienced directors who will be actively involved in guiding the Company."

The Company's management also reaffirms its previously issued guidance of $73.6 million in revenues and $21.4 million in net income for fiscal 2010. Management is confident in the Company's performance for the rest of the year and looks forward to updating investors on Lotus' third quarter results in the 10-Q filing and earnings release, which are scheduled to be released on or before Monday, November 15.

Lotus' management team will also be traveling to multiple cities in the U.S. to meet with brokers and institutional investors in early November. The circuit will involve meetings and presentations in San Francisco, Los Angeles, Phoenix, Chicago, and New York between Thursday, November 4 and Tuesday, November 9. Financial professionals who are interested in meeting with Lotus' management can contact Jon Cunningham at (407) 644-4256, Ext. 107 or Jon@redchip.com.

About Lotus Pharmaceuticals, Inc. Lotus Pharmaceuticals, Inc. is a fast-growing, profitable developer and producer of drugs and a licensed national seller of pharmaceutical items in the People's Republic of China (PRC). Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular diseases, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drug stores in 30 provinces of the PRC.

Information Regarding Forward-Looking StatementsExcept for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product demand, market competition, and risks inherent in our operations. These and other risks are described in our filings with the U.S. Securities and Exchange Commission.Contacts:At the Company:Xing Shen, Ph.D.VP of Corporate DevelopmentLotus Pharmaceuticals, Inc.Ph: 415-690-7688Email: shen@lotuspharma.comWeb: http://www.lotuspharma.comInvestor Relations:Jon CunninghamRedChip Companies, Inc.Tel: +1-800-733-2447, Ext. 107Email: info@redchip.comJing Zhang, ChinaRedChip Beijing Representative OfficeTel: +86 10-8591-0635Web: http://www.RedChip.com
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
2. Lotus Pharmaceuticals Announces Two Senior Management Appointments
3. Lotus Pharmaceuticals Announces Engagement of RedChip Companies to Lead Public and Investor Relations Efforts
4. Lotus Pharmaceuticals Enter R-Bambuterol(R) Clinical Trial I
5. Lotus Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results
6. Lotus Completed R-Bambuterols Pilot Scale Production for Clinical Trials
7. Lotus Pharmaceuticals Terminates SEDA
8. Lotus Pharmaceuticals to Present at Global Hunter Securities 2010 China Conference
9. Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform
10. Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results
11. Lotus Pharmaceuticals Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Feb. 20, 2017   AT&T 1 ... and treat patients with cardiovascular disease faster. The ... for ZywiePro, Zywie,s cardiac remote monitoring solution. The ... . AT&T and Zywie are looking ... with the disease. The Internet of Things (IoT) ...
(Date:2/20/2017)... Feb. 20, 2017 Seal Shield LLC ( ... solution for mobile device management and disinfection, the ElectroClave™, ... and Exhibition in Orlando, Fla. ... Mobile devices have become commonplace in today,s healthcare landscape, ... set of concerns, including the disinfection and tracking of ...
(Date:2/20/2017)... 20, 2017 Research and Markets has announced ... Market Analysis and Trends - Product (RFID refrigerators and RFID freezers), ... report to their offering. ... The Global RFID Blood Refrigerator and Freezer Market ... 2015 to 2025. This industry report analyzes the ...
Breaking Medicine Technology:
(Date:2/18/2017)... ... February 17, 2017 , ... ... drvallecillos.com , Beverly Hills plastic surgeon Dr. Glenn Vallecillos experiments ... Dr. Vallecillos says, "Traditionally, plastic surgery has been centered around that idea that ...
(Date:2/18/2017)... , ... February 18, 2017 , ... ... Use Pixel Film Studios ’ ProParagraph Fashion Volume 2 for all ... many other applications. Users can pick and choose from hand-crafted trend-setting designs ...
(Date:2/17/2017)... ... 2017 , ... Smiles by Seese is a comprehensive family dental practice ... leads the practice as a skilled and highly credentialed dentist who is qualified to ... patients of all ages with excellence in general, restorative, and cosmetic dentistry . ...
(Date:2/17/2017)... Diego, CA (PRWEB) , ... February 17, 2017 ... ... initiative—InvestUp—to focus on foundational and sustainable systems change designed to further positively impact ... , “The Board of Trustees has long considered it our duty to seriously ...
(Date:2/17/2017)... ... February 17, 2017 , ... For the ... management solution to the exhibit floor for the 2017 HIMSS Conference & ... From Feb. 19–23, 2017, more than 40,000 healthcare industry professionals are expected at ...
Breaking Medicine News(10 mins):